07.12.2012 Views

Full (127 KB) - Bahrain Medical Bulletin

Full (127 KB) - Bahrain Medical Bulletin

Full (127 KB) - Bahrain Medical Bulletin

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>Bahrain</strong> <strong>Medical</strong> <strong>Bulletin</strong>, Vol. 34, No. 1, March 2012<br />

1<br />

Detection of Multidrug-Resistant Tuberculosis Using PCR Compared to the Conventional<br />

Proportional Method<br />

Mogahid M Elhassan, PhD* Samar M Saeed, Msc** Miskelyemen A Elmekki, PhD***<br />

Ahmed A Al-Jarie, MD**** Mohamed E Hamid, PhD*****<br />

Objective: To evaluate the PCR technique for the rapid defection of Multidrug-Resistant (MDR)<br />

Mycobacterium tuberculosis compared to the conventional proportional drug sensitivity testing.<br />

Design: Cross sectional laboratory based study.<br />

Setting: Alshaab Teaching Hospital, Abu-Angah Hospital and the National Health Laboratory,<br />

Sudan.<br />

Method: One hundred thirty tuberculosis suspected individuals of both sexes and of different<br />

ages were included in the study. Sputum samples were cultured on Lowenstein-Jensen (LJ)<br />

medium. Resistant strains were tested for the presence of mutations conferring resistance using<br />

molecular techniques to amplify 315 base pair (bp) rifampicin (RIF) and 146 bp isoniazid (INH),<br />

as markers for MDR among Mycobacterium tuberculosis.<br />

Result: One hundred nineteen (91.5%) showed Mycobacterium tuberculosis-like colonies, 65 of<br />

which were randomly subjected to PCR and examined for the presence of IS6110 insertion<br />

sequences. Fifty-six (86.2%) were confirmed members of the Mycobacterium tuberculosis. The<br />

result of antibiotics susceptibility testing revealed that 32/56 (57.1%) of the strains were resistant<br />

to RIF, 36/56 (64.3%) to INH and 30/56 (53.6%) were resistant to both drugs (MDR). The<br />

conventional method showed 21/56 (37.5%) were resistant to RIF, 32/56 (57.1%) to INH and<br />

16/56 (28.6%) were resistant to both drugs (MDR).<br />

Conclusion: Not all resistant strains detected by conventional were detected by PCR method; 14<br />

(25%) were missed for RIF, 9 (16.1%) for INH and 4 (7.1%) for both. This represents a<br />

significant lack of sensitivity of the PCR technique, which could be due to the presence of other<br />

types of mutations that needs other primers and PCR protocol.<br />

<strong>Bahrain</strong> Med Bull 2012; 34(1):<br />

____________________________________________________________________________<br />

* Associate Professor and Head<br />

Department of Microbiology<br />

** Lecture and Researcher<br />

Department of Microbiology<br />

Sudan University of Science and Technology<br />

*** Assistant Professor of Immunology and Head Department of Parasitology<br />

Sudan University of Science and Technology<br />

**** Consultant of Pediatrics Infectious Diseases and Dean College of Al-Ghad International<br />

<strong>Medical</strong> Science Colleges, KSA<br />

***** Associate Professor and Consultant of Microbiology<br />

Tuberculosis Research Group, Department of Microbiology<br />

King Khalid University, KSA<br />

Email: mogahidelhassan@yahoo.com<br />

1


2<br />

The most effective anti-TB drugs are isoniazid (INH) and rifampicin (RIF). Resistant Mycobacteria to<br />

at least one of these drugs are the cause of Multidrug-resistant tuberculosis (MDR-TB). This type of<br />

resistance is highly problematic due to limited sources of drugs as well as the high toxicity, low<br />

efficacy and high cost of second-line tuberculosis drugs 1 .<br />

In 2008, an estimated 390,000 - 510,000 cases of MDR-TB emerged globally. Among TB cases, 3.6%<br />

are estimated to have MDR-TB. Twenty-two of 48 African countries reported first-line TB drug<br />

resistance, the estimated number of MDR-TB cases (primary and acquired) in 2008 was 69,000<br />

(53,000 - 110,000) 2 .<br />

Since the early study by Cavanagh, data on drug resistant TB are lacking in the Sudan 3 . Tuberculosis<br />

control program in Khartoum 2006 showed that there was no system to detect the prevalence of MDR-<br />

TB or HIV among the TB cases 4 .<br />

Although the rate of drug resistance is continuously increasing, only around 7% of estimated cases are<br />

detected. The control of drug resistant disease is difficult especially in high burden countries due to<br />

poor laboratory services and the slow nature of conventional drug susceptibility testing 5 .<br />

Therefore, implementation of rapid molecular methods for detecting drug-resistant TB may be a viable<br />

alternative to culture-based DST. Recently the WHO recommended the use of molecular techniques<br />

such as Line probe assay (LPA) for rapid screening of MDR-TB in low and middle-income settings 6 .<br />

The role of mycobacterial catalase-peroxidase gene (katG) was determined by cloning and sequencing<br />

of this gene. Mutations in this gene were found in 42 - 58% of isoniazid-resistant clinical isolates,<br />

confirming the effect of KatG enzyme in INH activity 7 .<br />

Other mutations were detected in Ser315Thr, about 40% of isoniazid-resistant strains 8 . This mutation<br />

was found to result in the production of a catalase enzyme that retains about 50% of isoniazid catalaseperoxidase<br />

activity, which is sufficient for the ability of the organism to evade the action of host active<br />

radicals 9 .<br />

Spontaneous mutations (deletions/substitutions/insertions) were found to occur in the 81-bp hotspot<br />

region of the rpoβ gene which encodes DNA-dependent RNA polymerase (the target for rifampicin<br />

binding); this result into replacement of the aromatic with non-aromatic amino acids in the target RNA<br />

polymerase enzyme, which consequently leads to poor bonding between rifampicin and the RNA<br />

polymerase 10,11 .<br />

The aim of this study is to evaluate the PCR technique for the rapid defection of MDR Mycobacterium<br />

tuberculosis in comparison to the conventional proportional drug sensitivity testing.<br />

METHOD<br />

Randomized prospective cross sectional study was performed. Smear-positive sputum was collected<br />

from 130 patients with persistent tuberculosis. Informed consent was obtained from each patient. The<br />

study was approved by the Federal Ministry of Health and the ethical committee of the Scientific<br />

Research Council of Sudan University of Science and Technology.<br />

Sputum samples were screened for acid-fast bacilli (AFBs) using Ziehl-Neelsen (ZN) smear<br />

microscopy. Handling and processing of specimens were performed in biosafety cabinet (BSL 3).<br />

Sputum was processed with the N-acetyl-L-cysteine-sodium hydroxide (NaOH) method (NaOH final<br />

concentration, 1.5%) and cultured in Lowenstein-Jensen (LJ) slants. Isolation and conventional<br />

identification of Mycobacterium tuberculosis were performed following standard method 12 . Drug<br />

susceptibility testing was performed by LJ proportion method 13 .<br />

2


3<br />

Sixty-five Mycobacterium tuberculosis isolates were randomly selected from the positive cultures and<br />

were confirmed as Mycobacterium tuberculosis by detecting species-specific IS6110 (123 bp) using<br />

primers and method previously described 14 . Resistant strains detected by conventional methods were<br />

tested for the presence of mutations conferring resistance to isoniazid (INH) and rifampicin (RIF)<br />

using PCR method.<br />

SPSS for windows version 11.0 was used for data analysis.<br />

RESULT<br />

One hundred thirty sputum specimens from patients were examined, 82 males and 48 females, age<br />

range was 12 to 67 years, 119 (91.5%) showed Mycobacterium tuberculosis-like colonies, 65 were<br />

randomly subjected to PCR and examined for the presence of IS6110 insertion sequences. PCR<br />

revealed that 56 (86.2%) were Mycobacterium tuberculosis and 9 (13.8%) were MOTTs, see table 1<br />

and figure 1.<br />

Table 1: Susceptibility Testing of IS6110 Positive Mycobacterium Tuberculosis for Rifampicin<br />

and Isoniazid by Proportion Method Compared to Multiplex PCR Method<br />

LJ proportion method PCR method<br />

RIF INH<br />

Number (%)<br />

RIF INH<br />

Number (%)<br />

Resistant 32 (57.1%) 36 (64.3%) 21 (37.5%) 32 (57.1%)<br />

Sensitive 23 (41.1%) 19 (33.9%) 35 (62.5%) 24 (42.9%)<br />

ND 1 (1.8%) 1 (1.8%) - -<br />

Total 56 56 56 56<br />

Figure 1: PCR Amplified IS6110 Sequences, Lane 1, DNA Marker; Lane 2, Negative Control;<br />

Lane 3, Reference Mycobacterium Tuberculosis Strain H37v (Positive Control)<br />

Antibiotics susceptibility testing revealed that 32/56 (57.1%) of the strains were resistant to RIF using<br />

the conventional proportion method compared to 21/56 (37.5%) using PCR method. Resistant for INH<br />

were 36/56 (64.3%) using the conventional method compared to 32/56 (57.1%) using PCR method;<br />

51.8% of the strains were found resistant for both drugs (MDR) using the conventional method<br />

compared to 28.6% for both drugs (MDR) using the PCR method, see figures 2 and 3.<br />

3


4<br />

Figure 2: The Amplicon of Rifampicin Resistant Mycobacterium Tuberculosis; Lane 1, DNA<br />

Marker; Lane 2, Negative Control; Lane 3, Positive Control; Lane 7; RIF Resistant Strain<br />

Figure 3: The Amplicon of Isoniazid Resistant Mycobacterium Tuberculosis; Lane 1, DNA<br />

Marker; Lane 2, Negative Control; Lane 3, Positive Control; Lanes 4 And 7, INH Resistant<br />

Strains<br />

DISCUSSION<br />

The result of antibiotics susceptibility testing revealed that there were obvious differences between the<br />

conventional and PCR method, this may be due to the presence of resistant mutations, which could not<br />

be detected using current primers.<br />

It was noticed that the majority of the isolates, which showed resistance to the two drugs on LJ<br />

medium proportion method showed resistance on the PCR to the two drugs or at least to one of them,<br />

mostly isoniazid; therefore, resistance to Isoniazid can be considered as a marker for multidrug<br />

resistance 15 . However, Sharma et al considered resistance to rifampicin as a marker for MDR TB 16 .<br />

In this study, a rising resistance rates of MDR among TB patients in Sudan compared with some<br />

African countries were revealed. In Ethiopia 14% of the isolates were found MDR, in Kenya 33.3%, in<br />

South Africa 60.2% and in Saudi Arabia 11% resistance to isoniazid and 9.7% to rifampicin was<br />

recorded 17-20 . In the present study, a rate of 21.5% was detected, which could be compared to Sharaf el<br />

Din et al who applied PCR based dot-blot method and found that 12% of strains were resistant to INH<br />

(katG gene), 8% were resistant to RIF (rpoB gene), 30% to STM (rpsl gene) and 4% to EMB (embB<br />

gene) but no record of MDR was investigated by these authors in patients with persistent TB 21 .<br />

Similarly, a novel PCR-based reverse hybridization method Genotype MTBDR assay (Hain<br />

Lifescience GmbH, Nehren, Germany) was evaluated for rapid detection of rifampicin (RIF) and<br />

isoniazid (INH) resistance in Turkish Mycobacterium tuberculosis isolates revealed that RIF resistance<br />

4


5<br />

was correctly identified in 95.1% of the isolates and in 73% of INH-resistant isolates. However, the<br />

recommendation of the author is to confirm the result with phenotypic methods 22 .<br />

The GenoType® MTBDRplus assay has been validated as a rapid and reliable first-line diagnostic test<br />

on AFB-positive sputum or MTB isolates for INH resistance, RIF resistance and MDR-TB in<br />

Bangkok, it was found reliable, but its impact on treatment outcome, feasibility and the cost associated<br />

with widespread implementation needs to be evaluated 23 .<br />

The presence of some isolates in this study, which are sensitive in the proportional method and<br />

appeared as resistant in the PCR to one of the two drugs or both of them could not be attributed to<br />

contamination, rather it could be due to mutations, which are not necessarily strongly related to<br />

resistance. Moreover, since the target region of the genes for RIF and INH resistance are not<br />

mentioned by the manufacturer, it is difficult to explain this part of the result.<br />

CONCLUSION<br />

Classical DST is still a gold standard method for diagnosis of MDR TB in developing countries.<br />

However, substitution of the classical DST with the rapid and sensitive PCR needs to be<br />

carefully evaluated as the protocol used in this study failed to detect all types of mutations<br />

present. Other PCR protocols targeting all known mutations in RIF and INH genes could be of<br />

more useful.<br />

___________________________________________________________________________<br />

Author contribution: All authors share equal effort contribution towards (1) substantial contributions<br />

to conception and design, acquisition, analysis and interpretation of data; (2) drafting the article and<br />

revising it critically for important intellectual content; and (3) final approval of the manuscript version<br />

to be published. Yes<br />

Potential conflicts of interest: No<br />

Competing interest: None Sponsorship: None<br />

Submission date: 30 March 2011 Acceptance date: 2 January 2012<br />

Ethical approval: The study was approved by the ethical committee of Federal Ministry of Health<br />

and the ethical committee of research council of Sudan University of Science and Technology.<br />

REFERENCES<br />

1. Migliori GB, Lange C, Girardi E, et al. Extensively Drug-resistant Tuberculosis Is Worse than<br />

Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same Results. Clin<br />

Infect Dis 2008; 46(6): 958-9.<br />

2. World Health Organization (WHO). Multidrug and Extensively Drug-resistant TB (M/X DR-<br />

TB): 2010 Global Report on Surveillance and Response. http://whqlibdoc.who.int/publications<br />

/2010/9789241599191eng.pdf. Accessed 17.2.2011.<br />

3. Cavanagh P. The Sensitivity to Streptomycin, PAS and Isoniazid of Strains of Myco.<br />

Tuberculosis Isolated from Patients in Khartoum and Wad Medani. Tubercle 1965; 46(3): 250-<br />

5.<br />

4. Ahmed Suleiman MM, Aro AR, Sodemann M. Evaluation of Tuberculosis Control Programme<br />

in Khartoum State for the Year 2006. Scand J Public Health 2009; 37(1): 101-8.<br />

5


6<br />

5. World Health Organization (WHO). Use of liquid TB Culture and Drug Susceptibility Testing<br />

(DST) in Low and Medium Income Settings. Summary Report of the Expert Group Meeting on<br />

the Use of liquid Culture Media. http://www.who.int/tb/laboratory/ use_of_liquid_tb_culture_<br />

summary_report.pdf. Accessed 25.1.2011.<br />

6. World Health Organization (WHO). Molecular line Probe Assays for Rapid Screening of<br />

Patients at Risk of Multidrug-Resistant Tuberculosis (MDR-TB): Policy Statement. Geneva,<br />

World Health Organization, 2008. http://www.who.int/tb/laboratory/1papolicy. pdf. Accessed<br />

12.2.2011.<br />

7. Somoskovi A, Parsons LM, Salfinger M. The Molecular Basis of Resistance to Isoniazid,<br />

Rifampin, and Pyrazinamide in Mycobacterium Tuberculosis. Respir Res 2001; 2(3): 164-8.<br />

8. Marttila HJ, Soini H, Eerola E, et al. A Ser315Thr Substitution in KatG is Predominant in<br />

Genetically Heterogeneous Multidrug-resistant Mycobacterium Tuberculosis Isolates<br />

Originating from the St. Petersburg Area in Russia. Antimicrob Agents Chemother 1998; 42(9):<br />

2443-5.<br />

9. Rouse DA, DeVito JA, Li Z, et al. Site-directed Mutagenesis of the katG Gene of<br />

Mycobacterium Tuberculosis: Effects on Catalase-peroxidase Activities and Isoniazid<br />

Resistance. Mol Microbiol 1996; 22(3): 583-92.<br />

10. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 Patients with Pulmonary<br />

Tuberculosis Resistant to Isoniazid and Rifampin. N Engl J Med 1993; 328(8): 527-32.<br />

11. Telenti A, Imboden P, Marchesi F, et al. Detection of Rifampicin-Resistance Mutations in<br />

Mycobacterium Tuberculosis. Lancet 1993; 341(8846): 647-50.<br />

12. Public Health Mycobacteriology, A Guide for a Level III laboratory. US Department of Health<br />

and Human Services, Public Health Service, Centers for Disease Control. USA: Atlanta, 1985:<br />

159-184.<br />

13. National Committee for Clinical Laboratory Standards (NCCLS). Susceptibility Testing of<br />

Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard; NCCLS<br />

document M24-A [ISBN 1-56238-500-3]. NCCLS, 940 Pennsylvania, USA: 2003.<br />

http://www.iso90.ir/phocadownload/csli/M24-A.pdf Accessed 17.3.2011.<br />

14. Eisenach KD, Cave MD, Bates JH, et al. Polymerase Chain Reaction Amplification of a<br />

Repetitive DNA Sequence Specific for Mycobacterium Tuberculosis. J Infect Dis 1989; 161(5):<br />

977-81.<br />

15. Vijdea R, Stegger M, Sosnovskaja A, et al. Multidrug-resistant Tuberculosis: Rapid Detection<br />

of Resistance to Rifampin and High or Low Levels of Isoniazid in Clinical Specimens and<br />

Isolates. Eur J Clin Microbiol Infect Dis 2008; 27(11): 1079-86.<br />

16. Sharma SK, Mohan A. Multidrug-resistant Tuberculosis. Indian J Med Res 2004; 120(4): 354-<br />

76.<br />

17. Bruchfeld J, Aderaye G, Palme IB, et al. Molecular Epidemiology and Drug Resistance of<br />

Mycobacterium Tuberculosis Isolates from Ethiopian Pulmonary Tuberculosis Patients with and<br />

without Human Immunodeficiency Virus Infection. J Clin Microbiol 2002; 40(5): 1636-43.<br />

18. Githui WA, Jordaan AM, Juma ES, et al. Identification of MDR-TB Beijing/W and Other<br />

Mycobacterium Tuberculosis Genotypes in Nairobi, Kenya. Int J Tuberc Lung Dis 2004; 8(3):<br />

352-60.<br />

19. Calver AD, Falmer AA, Murray M, et al. Emergence of Increased Resistance and Extensively<br />

Drug-Resistant Tuberculosis Despite Treatment Adherence, South Africa. Emerg Infect Dis<br />

2010; 16(2): 264-71.<br />

20. Alrajhi AA, Al-Barrak AM. Mycobacterium Tuberculosis Susceptibility in Saudi Arabia. Saudi<br />

Med J 2002; 23(10): 1227-31.<br />

21. Sharaf-Eldin GS, Saeed NS, Hamid ME, et al. Molecular Analysis of Clinical Isolates of<br />

Mycobacterium Tuberculosis Collected from Patients with Persistent Disease in the Khartoum<br />

Region of Sudan. J Infect 2002; 44(4): 244-51.<br />

22. Cavusoglu C, Turhan A, Akinci P, et al. Evaluation of the Genotype MTBDR Assay for Rapid<br />

Detection of Rifampin and Isoniazid Resistance in Mycobacterium Tuberculosis Isolates. J of<br />

Clin Microbiol 2006; 44(7): 2338-42.<br />

6


7<br />

23. Anek-Vorapong R, Sinthuwattanawibool C, Podewils LJ, et al. Validation of the GenoType®<br />

MTBDR Plus Assay for Detection of MDR-TB in a Public Health Laboratory in Thailand.<br />

BMC Infect Dis 2010; 10: 123.<br />

7

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!